Our History

We can trace our UK history back to Yorkshire in the 1930s when we were known as APS, or Approved Prescription Services. The business was founded by 2 women, (which would have been highly unusual back then) Mrs Margaret Galloway and Mrs Nora Sarsby, they opened the first premises in Bradford manufacturing pharmaceuticals.

Mr Walton bought out the 2 original founders and ceased trading as APS, but continued to market and sell APS products through Kempac, his own company.

In the 1940s Mr Wallace Hemmingway joined as Company Secretary in Batley based Kempac, as did Mr Stanley North in the role of Dispatch Manager. These two men became the driving force behind the revitalisation of APS.

Kempac's focus shifted from proprietary medicines and household remedies to the production of saccharine tablets which were in high demand during the war years because of the rationing of sugar.

The National Health Service came into existence on 5 July 1948. It was the first universal health system to be available to all and financed from taxation. It was founded on the fundamental principle that healthcare would be free at the point of access.

Since then, the NHS has gone through many changes, improvements, updates and modernisation processes. No-one back in 1948 would have been able to foresee the way in which the NHS developed, succeeded, pioneered and expanded.

Today Teva is one of the largest suppliers of medicines to the NHS and as you'd expect the NHS is our largest customer.

Amber Pharmaceuticals Limited bought the profitable Kempac operation, and with the increased availability of sugar driving down sales of saccharin, Amber Pharmaceuticals refocussed the production on own versions of popular branded medicines.

In the same year as the charge of one shilling was introduced for prescriptions, Amber Pharmaceuticals decided to close down the Batley factory, but 3 men from the pre Amber Pharmaceuticals era joined forces with 2 new investors to raise the capital needed to purchase the Batley plant and machinery from Amber Pharmaceuticals.

With the APS name still owned by Mr Walton from when Kempac purchased the APS business, the new phoenix company was reborn 16 years after it was originally founded and called APS once again.

Over a decade of successful trading and growth saw APS outgrowing the capacity of the Horncastle Street factory and in 1966, APS bought new premises in Whitcliffe Road, Cleckheaton.

APS enjoyed decades of steady growth through the production and sales of generic medicines, producing an average of 600 million tablets a year from the factory in West Yorkshire.

Meanwhile, over the Pennines in Cheshire, Steripak was established in 1980 by John & Ernest Prebble and Schering AG with ten employees and one production machine. It started off making wound irrigation bottles for hospital use and grew from there to produce a range of sterile pharmaceutical products.

In the 1980s, the generic pharmaceutical industry was hit by a price war as rival companies battled to grab a larger slice of the market for themselves. 

APS continued to develop new improved drug presentations, such as film coated or sustained release pharmaceutical products.

1985 saw both Applied Prescription Services' 50th anniversary and the government introduced the 'Selected List Scheme' which encouraged GPs to prescribe fewer brand name drugs and to switch instead to the cheaper unbranded generics to save the NHS millions of pounds a year.

If you fast forward to today, more than a billion items are prescribed generically every year. The increase of generic prescriptions, allied with a reduction in the net ingredients costs, means that overall savings to the NHS medicines bill have now passed more than £18 billion annually. 01

As one of the leading generic medicines suppliers in the UK, Teva was responsible for £2.4 billion of these savings in 2024 –that’s the equivalent of more than 96,000 new nurses or over 38,000 GPs.02

Waverley Pharmaceuticals acquired Steripak from Schering AG in 1987 and the first batch of products was produced in October with 34 people employed. Within two years, the workforce based in Runcorn, Cheshire had increased to over 200.

Berk, a success in its own right selling a range of branded and unbranded generics, merged with APS in 1991, creating APS/Berk, one of the largest generic pharmaceutical companies in the UK.

In 1992 Steripak was bought by the IVAX Corporation of Miami (including the site in Runcorn, Cheshire) and becomes part of the Norton Healthcare Group of Companies specialising in generics.

In 1996 APS/Berk was acquired by Teva Pharmaceutical Industries Ltd from Rhone-Poulenc Rorer Holdings Ltd. For Teva this represented a valuable entry into the UK market. For APS/Berk, Teva had the size and scale of an international pharmaceutical company to support the activities in the UK and to continue to deliver value to the NHS.

Norton Healthcare Group changes its name to IVAX Pharmaceuticals UK Ltd in 2001.

In 2004, APS/Berk updated its name to Teva UK Limited.

Manufacturing in Runcorn moved to its current home in Preston Brook in 2004, thanks to a significant investment in its sterile manufacturing facilities. The investment brought with it advanced capabilities for Blow-Fill-Seal production and the development of respiratory nebulisation products, which are important in helping people suffering from severe asthma or pulmonary disease.

The basic concept of Blow-Fill-Seal is that a container is formed, filled, and sealed in a continuous process without human involvement, in a sterile enclosed area inside a machine.

In 2006 Teva Pharmaceutical Industries acquired the Ivax Corporation, bringing together Teva's portfolio of generic medicines with a wider variety of products and new capabilities in respiratory care and branded pharmaceuticals in therapy areas such as central nervous system and oncology.

The sterile manufacturing site at Runcorn becomes part of Teva through the acquisition of IVAX Pharmaceuticals.

In 2009 we moved our commercial head office to Castleford, West Yorkshire. "Ridings Point" is a modern logistics centre, complete with fantastic offices and comprehensive facilities for our employees.

Our distribution centre is full of every kind of automated technology you'd expect from an organisation the size of Teva. Its streamlined systems make sure our medicine packs, boxes and pallets arrive safely with the pharmaceutical wholesaler and ultimately get to pharmacies and patients.

With 25,000 storage spaces covering the equivalent of three football pitches, it's an impressive sight. It was built to the highest pharmaceutical standards of Good Manufacturing Practice, and it shows our commitment to investing in the availability and sustainability of medicines.

Teva Runcorn adds additional capacity to its site, including Pre-Filled Syringe manufacturing capabilities as its range of products developed and manufactured here in the UK increases.

Learn more about what it's like working at Teva Runcorn and take a look inside the manufacturing process.

Teva's Harlow site - home to many of our Medical, Legal, Regulatory and Marketing teams - moves into new offices to accommodate growing teams.

Our UK based Regulatory Affairs teams are highly regarded within Teva and provide a Centre of Excellence for Regulatory Affairs for Teva's global business.

Teva Runcorn invests further in Sterile R&D and Sterile Device Technology with the expansion to create a sister site close to the manufacturing facilities, dedicated to the development of sterile devices, complete with hi-tech research and laboratory facilities.

The Sterile Device Technology works on the development of medical devices and combination products, such as auto-injectors and pre-filled syringes, which dispense drugs into the body.

Further investment in Teva Runcorn creates a state-of-the-art training facility which is the home of Teva's Sterile Training Academy which provides training programs in the philosophy and practice of all aspects of sterile pharmaceutical manufacturing.

480 million doses of medicine and counting… Go behind the scenes at Teva's UK sterile manufacturing facility in this video.

Teva acquired Actavis Generics in 2016, significantly expanding Teva’s generic product portfolio, R&D capabilities, product pipeline and global operational network.

For the UK it significantly increased our consumer healthcare range adding well known household names, such as Sudocrem^® and Infacol^® to our portfolio, as well as adding to our manufacturing and R&D sites with an additional facility at Larne, Northern Ireland, which focuses on branded and generic developments in medical implants and intrauterine devices.

The 2019 Health and Care Innovation Expo for the NHS was a unique celebration of innovation, enterprise and collaboration, bringing together NHS and social care leaders, commissioners, industry influencers and many more who can help the NHS implement its future plans to transform the UK’s 70-year-old healthcare system.

We shared our refreshed logo and our new updated visual identity. The refreshed brand is a symbol of everything we stand for and it showcases our renewed focus on the pharmacies we work with and their impact on patients; our care for patients with multiple chronic conditions; and the services and products we offer to carers to try to help make their lives a little easier.

During the development of the new brand identity, Teva researchers spoke to more than 1,000 patients from across the UK about how best to support them in taking control of their own health and wellbeing. As a result, Teva launched a new digital platform in the UK called Life Effects™, the platform is shaped by patients for patients, and shines a light on their real-world experiences and stories.

Life Effects™ offers information, insight and inspiration for people living with one or more chronic conditions. Developed in collaboration with patients, it looks at how health and illness affects the lives of patients and those around them in a profound way that goes much further than the biology of illness and treatment.

2020 was a year of global upheaval, and throughout it, we remained focused on ensuring uninterrupted access to essential medicines for patients worldwide. Our teams worked across Teva to keep research, manufacturing, and distribution running smoothly, while collaborating with government and industry bodies to support medicine supply during the crisis.

In the UK, we stood behind the NHS and frontline healthcare workers, donating over 100,000 tubs of Sudocrem® to help ease PPE-related discomfort. Like many, we were inspired by the dedication of healthcare professionals who led the Covid-19 response with courage and resilience.

Internally, we prioritised employee safety and well-being, swiftly reducing on-site staffing and following local health guidelines. Despite the challenges and physical distancing, our teams came together with a shared commitment to patients, colleagues,

From our humble beginnings, to shaping the worldwide generic medicine industry, we are now embarking on a new biopharmaceutical journey. We offer the world's largest medicine cabinet, providing medicines to about 200 million people around the world every day.03

With one of the most competitive operational networks in the industry, we now produce 1,800 unique molecules and a portfolio of 3,500 products, spanning generics, specialty and over the counter medicines. Through our Pivot to Growth strategy, we are focused on continuing to lead our business forward, improving the lives of patients around the world.